{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:03:18Z","timestamp":1784606598655,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.4065\/78.6.687","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:20:27Z","timestamp":1232760027000},"page":"687-695","source":"Crossref","is-referenced-by-count":246,"title":["Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial"],"prefix":"10.4065","volume":"78","author":[{"given":"Ananias C.","family":"Diokno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney A.","family":"Appell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger R.","family":"Dmochowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M.","family":"Gburek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira W.","family":"Klimberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherron H.","family":"Kell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11, suppl","key":"10.4065\/78.6.687_bib1","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.4065\/78.6.687_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0029-7844(01)01464-8","article-title":"Annual direct cost of urinary incontinence","volume":"98","author":"Wilson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.4065\/78.6.687_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0090-4295(97)00623-7","article-title":"Economic costs of urinary incontinence in 1995","volume":"51","author":"Wagner","year":"1998","journal-title":"Urology"},{"issue":"11, suppl","key":"10.4065\/78.6.687_bib4","first-page":"S574","article-title":"Comorbidities associated with overactive bladder","volume":"6","author":"Brown","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.4065\/78.6.687_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00005392-199907000-00020","article-title":"Urinary incontinence and depression","volume":"162","author":"Zorn","year":"1999","journal-title":"J Urol"},{"key":"10.4065\/78.6.687_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1067\/mob.2002.124839","article-title":"Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence","volume":"187","author":"Melville","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.4065\/78.6.687_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1532-5415.1990.tb03504.x","article-title":"Prevalence and incidence of urinary incontinence in community-dwelling populations","volume":"38","author":"Herzog","year":"1990","journal-title":"J Am Geriatr Soc"},{"key":"10.4065\/78.6.687_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1001\/jama.280.23.1995","article-title":"Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial","volume":"280","author":"Burgio","year":"1998","journal-title":"JAMA"},{"key":"10.4065\/78.6.687_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0029-7844(99)00661-4","article-title":"Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence","volume":"95","author":"Versi","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.4065\/78.6.687_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/009127009903900313","article-title":"Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin","volume":"39","author":"Gupta","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/78.6.687_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","article-title":"Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine","volume":"40","author":"Olsson","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/78.6.687_bib13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence","volume":"161","author":"Anderson","year":"1999","journal-title":"J Urol"},{"key":"10.4065\/78.6.687_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.4065\/78.6.687_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/78.6.687_bib16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"key":"10.4065\/78.6.687_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.4065\/78.6.687_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.1998.00501.x","article-title":"Efficacy and safety of tolterodine in participants with detrusor instability: a dose-ranging study","volume":"81","author":"Rentzhog","year":"1998","journal-title":"Br J Urol"},{"key":"10.4065\/78.6.687_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","article-title":"Dose-ranging study of tolterodine in patients with detrusor hyperreflexia","volume":"17","author":"Van Kerrebroeck","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"10.4065\/78.6.687_bib20","series-title":"Physicians' Desk Reference","first-page":"2803","year":"2002"},{"key":"10.4065\/78.6.687_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/78.6.687_bib22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1089\/jwh.1998.7.1263","article-title":"Urge incontinence: the patient's perspective","volume":"7","author":"Brown","year":"1998","journal-title":"J Womens Health"},{"key":"10.4065\/78.6.687_bib23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1532-5415.2002.50203.x","article-title":"Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients","volume":"50","author":"Zinner","year":"2002","journal-title":"J Am Geriatr Soc"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611624579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611624579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:58:28Z","timestamp":1684868308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611624579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["S0025619611624579"],"URL":"https:\/\/doi.org\/10.4065\/78.6.687","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}